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ABSTRACT 
Tissue injury/scarring of the vocal folds (VFs) can be caused by various factors including 
external trauma, cancer treatment or inflammation, leading to damage within the vibrating 
layers and a decrease in viscoelastic functions. These effects ultimately result in severe voice 
problems. This condition leads to significant morbidity for patients. Approximately 5-20% 
of the population in Western countries suffer from chronic hoarseness and/or a voice disorder. 
Currently, there are no effective treatments available.  
 
Embryonic stem cells (ESCs) are pluripotent cells that can different into various cell types or 
tissues in the body. They are powerful candidates for cell therapy for many diseases. 
Mesenchymal stromal cells (MSCs) have been considered as a valuable source in 
regenerative medicine due to their immunomodulatory properties, ability to self-renew and 
multipotency. The overall aim of this PhD project was to identify whether stem cells, and in 
particular local injection of MSCs can modulate the early inflammatory response within 
scarred VFs, and promote the wound healing process. We have used a combination of in vitro 
and in vivo models to address the fundamental questions, before translating our findings to a 
clinical phase I/II trial evaluating the safety and efficacy of autologous MSC injection on 
vocal function in patients suffering with severe voice problems. 
 
In study I, in a xenograft model, we showed that local injection of human embryonic stem 
cells (hESCs) induces sustained enhanced healing properties in injured VFs. Measurement 
of tissue viscoelasticity demonstrated improved function of VFs. Histological findings show 
a reduction in type I collagen and lamina propria (LP) thickness  in hESC treated VFs 
compared to untreated VFs. Moreover, no hESCs derivates (teratoma and malignances) were 
observed in the transplanted VFs. 
       
In study II, we examined how MSCs modulate the early inflammatory response within 
injured rabbit VFs. Histological examination demonstrated that injected MSCs were able to 
reduce tissue inflammation, further corroborated by findings confirming a significant 
reduction in mRNA expression of the pro-inflammatory markers, interleukin (IL)-1β and IL-
8. These findings were attributed to the ability of MSCs to reduce the level of cell death at 
the injury site and promote an anti-inflammatory milieu, as evidenced by increased levels of 
CD163+ cells. Despite low level persistence of the MSCs within the tissue, long-term effects 
on tissue repair were evident, with improved organization of the collagen matrix.        
                 
Limitations, in terms of cell suspension leakage and retention of MSCs at the site of injury 
have been reported with the use of liquid delivery vehicles. Study III therefore addressed 
these issues, evaluating the effectiveness of MSC delivery to injured VFs in a hyaluronan 
(HA) hydrogel carrier. Our findings demonstrated that HA was non-immunogenic, with no 
adverse events reported, and degraded within the VF tissue within 1 month. Complementary 
in vitro studies demonstrated that while the HA hydrogel delayed the migration of MSCs, 
these cells remained responsive to their extracellular environment, including pro-
inflammatory cues. The presence of a collagen matrix, as seen within the VF tissue, enhanced 
movement out of the gel potentially explaining why hydrogel delivery did not enhance 
persistence of the MSCs in the tissue. The study concluded that HA hydrogels may offer a 
safe and practical means to deliver MSCs to the VF, with minimal leakage, but no additional 
therapeutic effect could be seen in comparison to MSCs in liquid suspension. 
 
Based on the findings from studies II and III, we performed a phase I/II clinical trial in 16 
patients with severe VF scarring suffering from severe voice problems (study IV). Patients 
were treated with a single injection of autologous MSCs, after surgical resection of scar 
tissue. The study reached its primary endpoint of safety, with no adverse side effects reported. 
Clinical evaluation using high speed laryngoscopy and phonation pressure threshold 
demonstrated improvement in VF viscoelastic function in 62-75% of patients, dependent on 
the parameter. Self-reporting by the patients, using the voice handicap index confirmed 
significant improvements in phonation in 50% of the patients, with no significant change in 
the remaining cohort.  
 
In summary, stem cells and stromal cells were found to improve healing in scarred VFs. 
Local administration of MSCs into injured/scarred VFs dampens inflammatory responses by 
decreasing cell death due to injury and promoting an anti-inflammatory milieu. Delivery of 
the MSCs in a HA hydrogel reduces cell leakage, but does not offer therapeutic advantages 
compared to MSCs alone. Despite low-level persistence and no engraftment within the VF 
tissue, MSCs exerted long-term effects resulting in functional tissue repair. Our in vivo 
animal studies demonstrating the mechanisms by which MSCs support tissue repair were 
translated to the clinical setting, with local administration of autologous MSCs improving 
VF function and reducing morbidities associated with poor phonation in the treated patients. 
We conclude that local injection of MSCs may offer a safe and novel option for the treatment 
of VF scarring.  
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1 INTRODUCTION  
 
Vibration of the vocal fold (VF) tissue within the larynx is important for voice production, 
and dependent on neuromuscular activity for gross movement and pliability during 
phonation(1). VF scarring, due to external trauma, radiation, iatrogenic causes, inflammation 
or surgical treatment for neoplasms, is considered to be the most common cause of severe 
voice problems(2). Abnormal wound healing within VF tissue results in scar formation due 
to large-scale replacement of the superficial layer of the extracellular matrix (ECM) with 
collagen type I deposition in the lamina propria (LP), interrupting the delicate balance 
between the viscosity of the superficial layer of the VFs and increasing tissue stiffness(3). 
The voice, in turn, becomes aphonic or breathy and the phonation threshold pressure (PTP), 
corresponding to ease of phonation, is elevated(4). Along with viscoelastic changes in the 
scar tissue, the shear strength of the VFs also changes so that the normal mucosal wave is 
diminished, or even absent, during phonation.  This results in a loss of voice control, 
hoarseness and vocal fatigue(5).   
 
1.1 ANATOMY OF THE VOCAL FOLD  
 
The microstructure of VF tissue is complex due to its foliated organization.  According to the 
body-cover theory proposed by Hirano(6), the VFs consist of a superficial layer (cover) 
comprised of epithelium, basal membrane and superficial lamina propria (SLP). The inferior 
layer (body) consists of deep lamina propria (DLP) connected to thyroarytenoid muscle, 
separated by a middle layer of lamina propria (MLP; Figure 1).  This distinct architecture 
enables the two functional units to vibrate individually, with the level of vibration influenced 
by many factors such as loudness, pitch and age(7).  
 
The junction between the epithelial layer and LP is known as the basement membrane zone 
or lamina densa, and consists of structural proteins such as type IV collagen. The SLP is 
found below the basement membrane zone, a region called Reinke’s space, which plays a 
crucial role in separating the mucosal cover from the VF body(8). The SLP layer contains 
loose connective tissue with few type III collagen or elastin fibers, whereas the MLP and 
DLP layers are characterized by a higher amount of elastin and collagen respectively(7).  
 
 
 
Figure 1: Schematic and histological images illustrating the layers of the vocal fold tissue. (A and 
B) Schematic illustration highlighting the layered structure of the vocal fold tissue. (B) Histological 
section through the rabbit vocal fold tissue, highlighting the epithelial, lamina propria (*) and 
thyroarytenoid muscle (^) layers. The deeper muscular layer is noted in the rabbit compared to 
human vocal fold tissue. Figure adapted with permission from Gray et al., 2000, Ann Otol Rhinol 
Laryngol 109: 77-85(7). 
 
* 
* 
^ ^ 
A B C 
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This layered structure is found in the freely vibrating membranous mid-part of the VF tissue, 
but the structure changes close to the attachment of the VF tissue in the anterior and posterior 
regions where the macula flavae is located. The macula flavae or nodulus elasticus is 
comprised of dense cellular masses, which together with their ECM, are necessary for 
conveying the viscoelastic properties of the VF. ECM components such as reticular, elastic 
collagenous fibers(9), and hyaluronan (HA)(10) are important for the vibratory functions of 
the VF. Stellate cells resident in the macula flavae show morphological and phenotypic 
differences from stromal fibroblasts in the VFs(11, 12). These cells have well developed 
intracellular organelles, and when activated, continuously synthesize LP ECM, and play an 
important role in both acute and chronic inflammation(13-15). 
 
Rabbit VFs are relatively similar to human VFs, based on their ultrastructure, ECM content 
and viscoelastic properties(5). While, rabbit VFs are covered with stratified squamous 
epithelium as seen in human VFs, the three-layered structure of the LP described above is 
not as clearly defined. Rabbit LP is divided into two layers, SLP and DLP with the vocal 
muscle extending deeper than the two layers seen in humans (Figure 1). The superficial layer 
of the LP is comprised primarily of loose ground substances that closely resemble those found 
in human VFs(16).    
  
1.2 EXTRACELLULAR MATRIX COMPOSITION OF THE VOCAL FOLD 
 
The fibrous (collagen & elastin) and interstitial (fibronectin, decorin and fibromodulin) 
proteins present within the layers of VF tissue play an important role in maintaining the 
vibratory mechanics involved with phonation.  
1.2.1 Collagen & elastin 
 
Collagen is one of the most abundant proteins in the human body and accounts for 
approximately 43% of the total protein present within the LP of VFs(17, 18). Collagen fibrils 
aggregate into large bundles of collagen fibers, and play a structural role in providing strength 
while maintaining the mechanical properties, shape and organization of the tissue, and 
directly interacting with cells, to regulate their cell proliferation, differentiation and 
migration(19). Collagen types I & III have been detected as key components in the VF 
tissue(17, 20). Type I collagen provides high tensile strength, while type III is found 
predominantly in tissues that require flexibility and elasticity(21).  
 
Although collagen does not support tissue stretch directly, it provides the strength to partner 
elastin’s stretch and recoil properties in the VF tissue(7, 22). Elastin fibers are composed of 
the elastin protein and associated fibrillar components such as elaunin and oxytalan. Elastin 
is an essential component of the VF ECM, constituting approximately 9% of the tissue in 
comparison to other connective tissues such as skin, where elastin makes up 2-4%(23). 
Elastin plays an essential role in phonation, with this fibrous protein, appearing as short 
compact fibers, responsible for tissue flexibility, strength and elasticity.  
1.2.2  Interstitial proteins 
 
Interstitial proteins, essential in cell-cell interactions, are collectively seen as protein chains 
connected to branched polysaccharides. The relationship and ratio of fibrous proteins such 
as collagen and elastin to the interstitial proteins are essential to VF function, modulating the 
biomechanical properties and also enhancing the oscillatory characteristics of the tissue. This 
family of proteins also have strong effects on tissue viscosity, fluid content, thickness of the 
   3 
LP layers, and also influence collagen fiber population density and size.  Interstitial proteins 
are divided into proteoglycans including HA, decorin and fibromodulin and glycoproteins, 
such as fibronectin(24, 25).  
1.2.2.1 Hyaluronan  
 
HA is a naturally occurring linear polysaccharide comprised of repeated units of D-
glucuronic acid and N-acetyl D-glucosamine, and ubiquitously found in the ECM of all 
tissues, especially mechanically active tissues, including the VF (Figure 2A)(26, 27). HA is 
negatively charged and interacts with water, acting as a space filler and shock absorber(27-
29). These functions are essential to the VF tissue vibratory function. Within the VF, the 
highest levels of HA are found in the infra-fold, co-localizing with the region where mucosal 
waves are initiated during phonation. In the absence of HA, studies have shown that there is 
significant impact on the regulation of tissue elasticity and stiffness, that leads to decreased 
vibration and VF function(30).  In addition to its biomechanical functions, HA, dependent on 
its chain length, can modulate cellular functions, such as motility, morphogenesis, adhesion, 
cell survival, apoptosis and metastasis(31-34). 
 
In the ECM, HA synthesis and degradation is strictly regulated, with HA chain half-life 
differing from less than a day in tissues with rapid turnover, such as the skin, to 2-3 weeks in 
articular cartilage(35, 36). HA synthesis and polymerization takes place at the inner face of 
the plasma membrane. Hyaluronan synthase isoenzymes (HAS1, HAS2 and HAS3)(37) use 
a two sugar nucleotide such as uridine diphosphate, glucuronic acid or UDP N-
acetylglucosamine to generate a polymeric chain, which translocates through the plasma 
membrane into the ECM (Figure 2B)(38-40). HA is degraded by enzymes of the 
hyaluronidase family (HYAL1-6). HYAL1 and 2 are principally involved in the degradation 
of HA within somatic cells, including those of the VF. These enzymes work in collaboration, 
with HYAL2 adhering to HA extracellularly via HA receptors e.g. CD44, cleaving the full-
length HA polymer in acidic endocytic vesicles, with HYAL1 further cleaving the HA 
oligomers using β-exoglycosidases (Figure 2C)(35, 36).  
 
 
 
Figure 2: The synthesis and degradation of hyaluronan (HA). (A) HA is composed of repeated units 
of D-glucuronic acid and N-acetyl D-glucosamine. (B) HA synthesis and polymerization takes place 
at the inner face of the plasma membrane, with monomeric units added to the chain by members of 
the hyaluronan synthase family. (C) Hyaluronan degradation occurs through the collaborative action 
of hyaluronidases (HYAL) found on the plasma membrane surface (HYAL2) and intracellularly 
(HYAL1) in association with lysosomal bodies. Figure is reproduced with permission from Dicker et 
al., Acta Biomaterialia, 2014, Apr;10(4):1558-70 (26) 
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1.2.2.2 Small leucine-rich proteoglycans and fibronectin 
 
The presence of small leucine-rich proteoglycans within the VF appear to be co-ordinated by 
layer and respective function. Decorin, found within the SLP, has an affinity to type I 
collagen that functions to decrease collagen fiber size in collagen fibril formation and 
regulate the bundle thickness(41). The core protein is decorated with a single 
dermatan/chondroitin sulphate chain. In addition to its interactions with collagen, decorin 
binds to transforming growth factor beta 1 (TGFβ1), a growth factor essential to the healing 
process and strongly linked to tissue fibrosis if unregulated(42).  
 
Fibromodulin, a keratan sulphate proteoglycan, is found particularly in the intermediate and 
deeper layers of the VF tissue, close to collagen and elastin(28, 29). Binding to a separate 
site on the collagen core protein to that occupied by decorin, fibromodulin can limit fibril 
formation. Strong links between fibromodulin and scarless wound healing have been 
reported, potentially through its ability to inhibit the activity of TGFβ1(43). 
 
Fibronectin is the most common glycoprotein in the ECM, essential to the wound healing 
process. It provides support, binding proteins and cells to the ECM. Through the presence of 
functional domain and cell binding regions, this glycoprotein can influence multiple cellular 
pathways, including chemotaxis, and can act as a scaffold for stromal cell migration. In the 
VF tissue, fibronectin is seen principally within the SLP and infrequently in the DLP(44).   
 
1.3 EMBRYONIC STEM CELLS  
 
Embryonic stem cells (ESCs) are pluripotent cells that can go through unlimited self-renewal 
and maintain the pluripotency to differentiate into any cell type in the body. During 
mammalian embryogenesis, the fertilized oocyte develops into a multicellular organism. 
ESCs are derived from the inner cell mass (ICM) of blastocysts after 5-6 days of fertilization. 
Human embryonic stem cells (hESCs) maintain pluripotency and are strictly regulated by a 
core set of transcriptional factors such as Oct4, Sox2 and Nanog (45, 46). hESCs have the 
developmental capacity to form all derivatives of three embryonic germ layers including 
endoderm, mesoderm and endoderm(47), and can be differentiated into various cell lineages 
utilizing supplements added into the culture medium(48). 
 
Several animal studies have been reported that use of hESCs differentiated into particular 
lineages improves tissue functionality. For instance, injection of oligodendroglial progenitors 
derived from hESCs have been reported to differentiate into neurons and astrocytes following 
transplantation and improve outcome in spinal cord injuries(49). Likewise injected 
cardiomyocytes enhance muscle contractile properties of the myocardium after myocardial 
infarction(50, 51). Similarly, pancreatic β cells derived from hESCs produce insulin and 
amylin, restoring pancreatic function in mice(52, 53).  
 
To date, three hESC based cell therapies have entered into clinical trials for spinal cord  
injury, macular  degeneration, and type I diabetes(54).  With the knowledge that hESCs can 
differentiate into different lineages such as muscle, epithelium, and cartilage, we 
hypothesized that these cells could help restore the function of scarred VFs. We have 
previously injected hESCs into injured rabbit VFs. The results from this study demonstrated 
tissue regeneration in the VFs, increased viscoelasticity and minimized scarring after 1 
month(55).  
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1.4 MESENCHYMAL STROMAL CELLS 
 
Mesenchymal stromal cells (MSCs), originally termed as mesenchymal stem cells, were first 
reported by Friedenstein in 1960(56). These bone marrow resident cells, were characterised 
by their plastic adherence, formation of colonies indicative of self-renewal capacity, and their 
propensity to differentiate into osteoblasts.  
 
Since then our knowledge of MSCs has grown exponentially. Discovery that these cells are 
immunomodulatory and key players in the wound healing process has undoubtedly 
influenced their development as a cell therapy. Since their initial report, stromal cell sources 
have also been validated in other tissues of fetal and adult origin, including fat, umbilical 
cord and dental pulp. These findings, and the development of MSC cell therapies from 
multiple sources, called for more stringent defining criteria, which was outlined by the 
International Society of Cell and Gene Therapy (ISCT) in 2006. These criteria state that an 
MSC must be able to demonstrate plastic adherence, self-renewal capacity, possess 
multipotent capability (cells able to differentiate into mesenchymal lineages; bone, fat and 
cartilage), express the cell surface markers CD90, CD73, CD105 and human leukocyte 
antigen (HLA) I, and be negative for the hematopoietic and fibrocyte surface markers CD45, 
CD34, CD31, CD19 and HLA II(57). 
 
These original guidelines remain limited by the fact that many stromal cell sources possess 
these phenotypic markers. No consideration is placed on the distinct molecular differences 
in MSC sources dependent on memory of their tissue of origin. It has therefore become 
increasingly apparent that in understanding the mode of action of an MSC, consideration has 
to be placed on its anatomical source. Likewise choosing an appropriate cell source for 
cellular therapies will be crucial in establishing therapeutic efficacy(58). 
 
1.5 LARYNGEAL DISORDERS  
 
Laryngeal disorders have a significant impact on voice quality, with almost one-third of the 
adult population experiencing dysphonia at some point during their lifetime(59). This 
condition is associated with a high degree of morbidity for the patient, impacting 
communication and the ability to work, leading to unemployment, isolation and 
depression(59-62). Damage to the vocal ligament (Figure 3) is present in 60-80% patients 
who suffer with severe dysphonia, strained phonation and reduced VF vibration(2, 63).  
 
Voice quality, pitch or loudness change significantly in vocal disorders, and are associated 
with other complaints such as vocal fatigue, pre-laryngeal pain, pharyngolaryngeal reflux, 
throat irritation and throat clearing. Vocal disorders disturb laryngeal function by changing 
the VF structure (organic disorders) and function (functional disorders). Organic disorders 
include physical changes in the VF tissue such as edema, or nodules and structural alterations 
in the larynx due to aging. In addition, problems with central or peripheral nervous system 
innervation in the larynx can affect vocal mechanisms, leading to disorders such as VF 
paralysis or spasmodic dysphonia. In contrast, functional disorders are associated with 
inefficient vocal vibration. The VF structure remains normal, however, there is vocal fatigue 
and the voice may be characterized by dysphonia or aphonia, ventricular phonation, and 
diplophonia. Work is ongoing to identify populations at risk for voice disorders, in order to 
develop early screening procedures(63, 64).  
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Figure 3: Anatomy of the human larynx.  The vocal folds are attached posteriorly to the arytenoid 
cartilage and anteriorly to the thyroid cartilage. This can be seen from the two cross-sectional 
viewpoints of the larynx above (location of the vocal folds are highlighted by red boxes on each 
image). The figure is adapted with permission from Miri AK, Journal of Voice, 2014, Nov;28(6):657-
67 (65). 
  
 
To identify the effect of age and gender on individuals who develop functional or organic 
voice disorders, Van Houtte’s team conducted a retrospective investigation on laryngeal 
pathology diagnosed using videostroboscopy(66). The findings from this study indicated that 
functional voice disorders are the most common (30%), with no cases seen in childhood. This 
was followed by VF nodule disorders (15%), and pharyngolaryngeal reflux disorders (9%). 
The pathologies were significantly higher in females (63.8%) than in males (36.2%). For 
professional voice users, functional dysphonia occurred in 41% of individuals, with teachers 
mainly affected(66). The majority of these pathological findings have been similarly 
demonstrated in a further study conducted on individuals between the ages of 45-64(63). 
 
The most commonly diagnosed changes to the voice come with age due to presbyphonia or 
VF atrophy. The VF tissue in elderly individuals undergoes significant changes leading to 
severe hoarseness, that is difficult to treat(67). VF scarring in the large spectrum, which may 
include VF atrophy, can be the result of sulcus vocalis, postsurgical scarring, phonotrauma, 
or direct trauma (radiation or reflux disease). Although the causes of VF scarring are distinct, 
the phonatory outcomes are similar in all conditions. Loss of phonation due to scarring results 
in mucosal wave impairments with loss of pliability and incomplete glottal closure(68). 
Pliability of the VF is significantly affected in this condition and presents as incomplete 
glottal closure due to thinning or bowing of the vocal cords. Sulcus vocalis is a long, thin 
groove running along the edges of the SLP of the VF. This defect can be restricted to the SLP 
or penetrate deeper into the DLP and muscle(69) (Figure 4). 
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Figure 4: Images taken using videostroboscope highlighting (A) scarring in the left VF (*) and slight 
atrophy in the right VF. (B) Bilateral sulcus vocalis, most evident in right VF (arrow). (C) Schematic 
representation of sulcus vocalis. Abbreviations: S - superficial LP; I -intermediate LP; D – deep LP;   
M – muscle. 
 
1.6 VOCAL FOLD SCARRING  
 
Damage to the VF tissue that disturbs ECM organization can change the viscoelastic 
properties of the VFs, resulting in hoarseness and poor voice quality. Severe damage due to 
direct injury or external trauma of VF tissue may lead to permanent pathological changes, 
with scar formation, inhibition of mucosal wave formation and dysphonia(70). Systematic 
approaches have been utilized to characterize the role of the ECM in VF wound healing and 
scarring in various animal models, including bovine, porcine, ovine and lapin systems, have 
been developed to examine the wound healing properties of VF tissue(71-76). The 
relationship between ultrastructural changes in the ECM, especially collagens, elastin and 
HA, as well as, the corresponding viscoelastic properties remains poorly understood.  
 
Fibrous scar tissue consists primarily of type I collagen, with stiffness of the scarred VF 
dependent on the collagen content and organization. Studies have demonstrated that, post-
injury, increased levels of type I procollagen are deposited in the SLP, and that the collagen 
composition is less dense and becomes disordered compared to healthy tissue. Similarly, 
injury results in a loss of elastin fiber density and organization. As the scar tissue develops 
with time procollagen levels increase, and although elastin levels are restored within the 
tissue, their organization, much like that of the collagen, remains unstructured, thereby 
impeding function(5, 71).  
 
Scar tissue is not solely composed of type I collagen and elastin. Recent research in the field 
has suggested a need to consider other ECM molecules including HA, fibronectin, decorin 
and other collagen types that can also regulate tissue viscoelasticity and function. Levels of 
HA may also influence wound healing and scar formation. Changes in HA density and 
distribution between scarred and healthy VFs have been investigated in both rabbit and 
canine models. Levels of HA were lower in injured VFs during the initial stages of wound 
repair compared to healthy controls. These data suggest that adding HA in the early stage of 
wound healing, or in the clinical situation, after resection of the scar tissue, may have an 
beneficial impact on decreasing the incidence of VF scar formation(77). 
 
A C B 
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Both decorin and fibromodulin have been reported to limit scarring within the injured VF 
through their ability to actively bind and inhibit TGFβ1, which up-regulates collagen 
synthesis by stromal fibroblasts, and has been directly linked to tissue fibrosis by converting 
fibroblasts into contractile, alpha smooth muscle actin (αSMA) expressing cells(29).  
 
Fibroblasts secrete an extensive network of fibronectin and type III collagen. Fibronectin has 
a stronger affinity to type III collagen than any other collagen type, which forms a primary 
constituent of granulation tissue. Over time, granulation tissue begins remodeling by 
decreasing fibronectin and type III collagen, as well as simultaneously increasing the content 
of type I collagen to later contribute to matrix organization(78). It was previously reported 
that high levels of fibronectin are present in hypertrophic and chronic wounds, and that the 
persistence of elevated levels of fibronectin in the ECM can lead to fibrosis during the healing 
process(79). This has been evidenced in scarred rabbit VFs 2 months post-injury(78, 80, 81). 
  
1.7 VOCAL FOLD WOUND HEALING  
 
In general, wound healing is a dynamic and complex process consisting of a series of co-
ordinated events between diverse immunological and biological systems. It commences with 
bleeding and coagulation, and evolves into acute inflammation, cell migration, proliferation, 
differentiation, angiogenesis, synthesis and remodeling of the ECM and re-epithelialization. 
These complex events can be divided into four overlapping time-dependent phases 1) 
hemostasis 2) inflammation 3) proliferation and 4) remodeling (Figure 5).  
1.7.1 Hemostasis  
 
Coagulation and hemostasis take place immediately after injury, to prevent exsanguination. 
The dynamic balance between endothelial cells, thrombocytes, coagulation and fibrinolysis 
regulates hemostasis and the reparative process. After injury, blood enters the injury site, and 
platelets begin to aggregate with collagen, and other ECM components. This initiates the 
formation of a blood clot composed of fibronectin, fibrin, vitronectin and thrombospondin. 
The platelets trapped within the clot provide a provisional matrix for cell migration in the 
later phases. This triggers the release of growth factors and cytokines, such as platelet-derived 
growth factor (PDGF), basic fibroblast growth factor (bFGF), epidermal growth factor, 
vascular endothelial growth factor (VEGF), and TGFβ1. These molecules act as promotors 
of the wound healing cascade, and attract immune cells (neutrophils, monocytes, 
lymphocytes) to the wound site. Cytokines released from immune cells including tumor 
necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), interleukin (IL)-1β, PDGF, bFGF 
and TGFβ1 further modulate fibroblast activation in the wound bed(82, 83). 
1.7.2 Inflammatory phase 
 
This phase begins after immune cells reach the site of injury. Neutrophils are the primary 
effector cells present 24 hours after injury. They are guided to the wound site by chemokines 
and other chemotactic agents such as TGFβ1, formyl-methionyl peptides from bacteria, and 
platelet products. These cells are implicated in the clearance of foreign material and bacteria 
by phagocytosis(83). Monocytes, which are the precursors of tissue macrophages appear in 
the wound after 48-72 hours and continue the process of phagocytosis. Monocytes are 
attracted to the wound by a myriad of chemoattractive agents, such as PDGF, TGFβ1, elastin 
and collagen breakdown products(84). Lymphocytes enter the wound 72 hours after injury 
by secretion of IL-1β, complement products and immunoglobulin G (IgG) breakdown 
products. IL-1β plays a crucial role in the later phase of collagen remodeling and synthesis 
   9 
of ECM components, and their degradation(85-87). Further discussion surrounding the role 
of the innate immune response in the wound healing cascade can be found in section 1.8. 
 
 
 
Figure 5: The stages of wound healing.  A schematic representation of the stages of the wound healing 
cascade and their associated key events.  
1.7.3 Proliferative phase  
 
The proliferative phase begins approximately 3 days after injury, and continues for 2 weeks, 
involving fibroblast activation, migration and the production and deposition of ECM, 
resulting in the formation of granulation tissue. In response to increased levels of TGFβ1 in 
the wound, fibroblasts change their phenotype into myofibroblasts, expressing αSMA. These 
myofibroblastic cells are involved in synthesizing and depositing ECM components. In this 
phase, fibroblasts enter the fibrin clot and release various matrix metalloproteinases (MMPs), 
which degrade the clot, replacing this with ECM components such as collagens I, III, IV and 
VII and glycoproteins such as fibronectin, proteoglycans, and HA. This complex matrix 
supports angiogenesis and re-epithelization(88).   
 
Myofibroblasts exhibit contractile properties and play a crucial role in the contraction and 
maturation of granulation tissue(89). When newly synthesized ECM forms, the cellular levels 
including myofibroblasts are decreased markedly around the scar tissue. This reduces 
stiffness, with the release of mechanical stress, and also decreases αSMA expression and 
contractibility of myofibroblasts. The excessive or redundant fibroblasts are eliminated by 
apoptosis or phagocytosis either by macrophages or neighboring cells(90-92). The internal 
connective tissue shrinks in size, and allows fibroblast interactions with the ECM. This 
process is highly regulated by PDGF, TGFβ1, and bFGF(93, 94). Moreover, the growth of 
capillaries is inhibited, leading to a decrease in blood flow and metabolic activity at the 
wound site. Eventually the mature scar tissue will consist of a reduced number of cells, and 
capillaries, and will display improved tensile strength(95, 96).  
1.7.4 Remodeling phase 
 
After formation of the scar tissue within the wound, the remodeling phase begins and may 
last for 1-2 years. During this time, proteolytic enzymes, MMPs and their inhibitors, tissue 
inhibitors of metalloproteinases, play an important role in regulating ECM synthesis and 
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matrix remodeling.  This phase is important in reversing tissue fibrosis, and restoring tissue 
architecture by maintaining the balance between degradation and synthesis, resulting in 
collagen remodeling and reorganization, and decreased levels of fibronectin and HA(86, 97).  
 
1.8 INNATE IMMUNE RESPONSE IN WOUND HEALING  
 
The innate immune system is the first line of defense in the wound healing process. It 
functions rapidly to eliminate the spread of infection. Its non-specific actions in the clearance 
of harmful agents is dependent on pathogen associated molecular patterns or damage-
associated molecular patterns through the toll-like receptor (TLR) system. The cells and 
molecules involved in this system are principally macrophages, neutrophils, mast cells, 
eosinophils, interferons, interleukins, anti-microbial peptides and proteins and acute phase 
proteins. These cells display various characteristics complementing each other’s functions by 
the production of inflammatory mediators through phagocytosis, production of reactive 
oxygen species, nitric oxide and antigen presentation(98, 99). Monocytes are the prominent 
cells in the inflammatory response that allow co-ordination between the innate and adaptive 
immune responses to improve host defense against pathogens.  
1.8.1 Monocytes and macrophages in tissue repair  
 
Monocytes are found in the blood, bone marrow, and spleen, and are recruited to the injury 
site during the homeostasis phase. They act as effector cells in their own right and as 
progenitors of macrophages and dendritic cells. Initially monocytes were characterized by 
their expression of CD14, and later the additional detection of CD16. Cell surface markers 
and functional activities distinguish heterogeneous types of monocytes, such as inflammatory 
(classical) or anti-inflammatory (non-classical) subsets. Human classical monocytes are 
CD14+CD16-, intermediate subsets express both CD14 and CD16 (as well as an increased 
level of HLA II), and non-classical monocytes are CD14-CD16+. The three subsets vary in 
expression of C-C chemokine receptors (CCR), adhesion molecules, and differentiation 
properties(100, 101). For instance, CD14+CD16+ monocytes express CCR5 and 
CD14+CD16- monocytes express CCR2(102).  
 
 
Figure 6: Schematic representation of monocyte differentiation into pro-inflammatory (M1) and anti-
inflammatory (M2) macrophages. Figure reproduced with permission from Takeya & Komohara, 
Pathology International, 2016, Sep;66(9):491-505(103)  
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Macrophages can respond to endogenous stimuli that are generated immediately after injury 
or infection. In addition, macrophages can also respond to signals coming from antigen-
specific or adaptive immune cells. In response to these environmental stimuli, macrophages 
demonstrate multidirectional polarization.  The subtypes of polarized macrophages are 
classified as classically activated or inflammatory macrophages (M1) and alternatively 
activated or anti-inflammatory macrophages (M2).  In response to pro- inflammatory 
cytokines such as TNF-α, IFN-γ and lipopolysaccharide (LPS), the macrophage activates and 
differentiates into an M1 phenotype. This subset of macrophages encourages inflammation 
by releasing pro-inflammatory cytokines (IL-12, IL-1ß, TNF-α, IL-6 and IL-23), as well as, 
reactive oxygen species and nitrogen intermediates, which can stimulate other immune 
populations. M1 macrophages are characterized by their expression of several markers 
including inducible nitric oxide synthase (iNOS), HLA-DR, CD80, CD86, and TLR 2 and 4 
(Figure 6). Up-regulation or failure to resolve the M1 macrophage response can lead to 
further damage in the tissue through activation of pathogenic T helper 17 cells(103, 104).  
 
M2 anti-inflammatory macrophages can be divided into 4 main subtypes, M2a-d, based on 
the applied stimuli. The M2a subset is induced by IL-4 and IL-13, M2b by immune 
complexes and LPS, M2c by glucocorticoids and TGFβ1 and M2d by adenosine and IL-
6(105, 106).  Collectively these macrophages are considered as anti-inflammatory mediators, 
stimulating wound repair by secreting factors such as IL-10, IL-13 and TGF-ß1. M2 
macrophages also stimulate phagocytosis of neutrophils, and promote the migration and 
proliferation of stromal fibroblasts, epithelial and endothelial cells to promote tissue repair, 
epithelialization and neovascularization(107, 108).  
 
Mature tissue macrophages express various cell surface receptors. Scavenger receptor is one 
type of group of pattern recognition receptors that has a broad range of ligand binding. 
Scavenger receptor cysteine-rich (SRCR) are a subgroup of the scavenger receptor family. 
The SRCR family is divided into group A and B based on the spacing pattern differences 
between their cysteine residues. Group A comprises of 6 cysteine residues, whereas, group 
B consists of 8 cysteine residues. The molecules included in group A are class A scavenger 
receptor I, Mac-2 binding, macrophage-associated receptor with collagenous structure, 
complement factor I and enterokinase(109).  
 
The transmembrane glycoprotein CD163 (130 kDa) belongs to the class B SRCR family, 
along with other molecules including CD5, CD6, SPα and gp-340. CD163 is expressed on a 
sub-population of mature tissue macrophages (strongly associated with M2a and M2c 
macrophages) and has been described in humans, marmosets and pigs (110-112). It is also 
described as an ED2 antigen (mature tissue macrophage) in rat(113). Previously it was 
reported that increased levels of CD163 expression were found in mature tissue macrophages 
including liver kupffer cells, red pulp macrophages in the spleen, macrophages in the thymus 
and resident bone marrow macrophages(114).  Typically, CD163 is considered to be a marker 
of anti-inflammatory macrophages, induced by glucocorticoids and anti-inflammatory 
mediators, such as IL-6 and 10(115, 116) (117, 118). However, reports have also 
demonstrated that IFN-γ and LPS can upregulate CD163. These seemingly opposing stimuli, 
illustrate the roles that CD163 plays in both suppressing inflammation, as well as, in the 
scavenging of damaged and dead cells/cellular debris(119).  
 
Both M1 and M2 macrophages play an important role in myofibroblast activation during 
fibrosis. Following the build-up of excessive inflammation in tissue, M1 macrophages can 
initiate the pro-fibrotic process by releasing various cytokines that recruit fibrocytes via 
chemokine (C-C motif) ligand 2 (CCL2), which then migrate to sites of inflammation and 
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promote the proliferation of myofibroblasts through release of MMPs that degrade the 
ECM(120, 121). When the acute phase of inflammation comes to an end, M2 macrophages 
are generated by stimulation of the aforementioned cytokines or via phagocytosis of apoptotic 
bodies, triggering anti-inflammatory processes through the release of IL-10, TGFβ1, arginase 
and heme oxygenase-1, aiding the transition to the proliferative phase of the healing 
process(122, 123).  
 
1.9 THE ROLE OF MESENCHYMAL STROMAL CELLS IN WOUND HEALING  
 
Several studies have shown that MSCs can migrate to injured tissue sites in response to the 
chemokine stromal cell-derived factor-1 (SDF-1), which interacts with its receptor C-X-C 
chemokine receptor 4(124-127). Although the role of endogenous MSCs in the VF has not 
been explored with respect to healing responses, knowledge regarding their ability to 
modulate the different stages of the healing cascade have been hypothesized from other 
tissues (Figure 7).  
 
In generic terms, during the inflammatory phase of the healing response, when MSCs are 
exposed to pro-inflammatory cytokines (TNF-α, IFN-γ and IL-1β), they become activated, 
resulting in the up-regulation of chemokine receptors such as macrophage-derived 
chemokine receptors (CCR2, CCR3, and CCR5),  which can mediate their migration to sites 
of injury(128-132). They furthermore, modulate their expression of chemokines and 
cytokines, such as IL-6, and iNOS, which can directly modulate both innate and adaptive 
immune subsets (including upregulating of regulatory T cells) to decrease the secretion of 
pro-inflammatory cytokines in favor of anti-inflammatory cytokines such as IL-10 and IL-4. 
These immunomodulatory properties and ability to sense environmental change make MSCs 
a potentially valuable therapeutic option for wound healing(133).  
 
MSCs have been shown to play a role in the recruitment of both monocytes and M2 
macrophages within inflamed tissue by the secretion of factors such as CCL1, CCL3, CCL12, 
chemokine (C-X-C motif) ligand 2 and macrophage colony-stimulating factor (M-
CSF)(134). Some studies have reported that MSCs can suppress tissue inflammation through 
skewing of M1 pro-inflammatory macrophages, or via direct induction of monocytes, to an 
M2 phenotype by cell-cell contact or by MSC secretion of prostaglandin E2 (PGE2), IL-6 
and indoleamine 2,3-dioxygenase (IDO)(135-137). This switch to an M2 phenotype is 
accompanied by activation of cytokines and growth factors that have anti-fibrotic properties 
including hepatocyte growth factor (HGF). The growth factor HGF can limit myofibroblast 
differentiation, and regulate fibroblasts in the wound to produce a more organized and 
regulated ECM akin to that of the native tissue(138, 139). Fibroblasts respond to HGF by 
specifically down-regulating the expression of TGFβ1 and type III collagen by nuclear 
exclusion of SMAD3, a transcriptional factor regulating various pro-fibrotic factors including 
TGFβ1. HGF also promotes the up-regulation of collagenases, MMPs 1, 3 and 13, in 
fibroblasts and M2 macrophages, hence promoting the turnover of ECM, and breakdown of 
scar tissue. 
 
During the proliferative phase of wound healing, MSCs secrete pro-angiogenic factors 
(VEGF, angiogenin and leptin), which increase the density of microvessels and improve 
tissue vascularization within the wound. MSC secreted growth factors, such as insulin-like 
growth factor 1, PDGF, TGFβ1, SDF-1 and HGF, also promote the migration and 
proliferation of vascular endothelial cells and fibroblasts(140, 141).   
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During the remodeling phase, MSC paracrine signaling may also promote an anti-scarring 
effect. MSCs secrete large amounts of VEGF and HGF, playing a role in maintaining higher 
ratios of the fetal, scarless healing form TGF-β3 to scar inducing TGFβ1(142).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: The multi-faceted role of the mesenchymal stromal cell (MSC) in tissue repair. MSCs have 
been exploited in tissue engineering and therapeutic applications for their immunoregulatory, anti-
fibrotic and multipotent properties. Figure reproduced with permission from Jackson et al. Stem Cells 
Translational Medicine, 2012, Jan;1(1):44-50(143).  
 
1.10 TREATMENT STRATEGIES FOR VOCAL FOLD DISORDERS 
 
Treatment options for the aforementioned VF disorders are organized under three main 
approaches.  
 
Voice therapy is an important part of treatment for various vocal disorders. This can take 
the form of: 
A) Direct or physiologic voice therapy, which directly alters the physiology of the vocal 
mechanism by practicing voice therapy methods such as the accent method(144), cup bubble 
blowing(145), expiratory muscle strength training(146), Lee Silverman voice treatment(147), 
stretch and flow phonation, and vocal function exercises(148).  
 
B) Indirect or symptomatic voice therapy treatment is aimed at modifying the deviant vocal 
symptoms or perceptual voice components using a variety of techniques. Deviant symptoms 
include changes in the voice pitch, volume and breathy phonation. Voice facilitating 
techniques such as amplification, auditory masking, chant speech, confidential voice therapy, 
semi-occluded vocal tract exercises, straw phonation and twang therapy are used to improve 
voice quality. The above treatments are selected based on the type and severity of the 
symptoms and the patient’s experience(149-153).  
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Medical treatments, such as proton-pump inhibitors used for anti-reflux, can help treat 
patients suffering with reflux laryngitis. Type A botulinum toxin, used to treat muscle 
disorders, has also been shown to be beneficial in the treatment of voice disorders caused by 
muscle spasms or spasmodic dysphonia(154). Surgical treatments have increased 
dramatically in recent years for the treatment of voice disorders. Phonomicrosurgery has been 
valuable in the removal of lesions or abnormalities that inhibit VF vibration(155), as well as, 
laryngeal framework surgery, which involves surgical manipulation of the larynx framework 
in order to enhance VF closure and improve vibration(156).  
1.10.1 Treatment strategies for vocal fold scarring  
 
Voice therapy for patients with VF scarring has demonstrated to be less effective in 
improving voice quality, while other options to resect scar tissue by surgery usually has 
limited effect and may even worsen the issue(157, 158). There is currently no effective 
treatment available to treat VF scarring. This complex condition, treated in clinical settings, 
produces inconsistent and suboptimal results, with the need for further understanding into the 
pathology and development of novel treatment options. 
 
Preclinical research for the development of novel treatments for VF scarring is mainly 
focused on two approaches: 1) prophylactic treatment or preventive approaches for 
attenuation of scar formation after injury of the VF tissue and 2) treatment of chronic scar 
tissue for restoration of vibration function.  
 
Prophylactic treatments are based on the concept that the acute healing phase serves as a 
critical period during which therapeutic intervention may attenuate eventual scar formation. 
From a clinical perspective, this approach would involve excision of the scar tissue to induce 
a wound healing response. In the acute wound, resident fibroblasts start to synthesize ECM 
2-3 days after injury(159). Prophylactic therapeutic interventions given at time of injury, in 
preclinical animal models, include MSCs, vitamin A, corticosteroids, HA-based biomaterials 
(discussed further below and in section 1.12) and decellularized scaffold materials.  
 
Previously, we have published the benefit of locally injecting human bone marrow MSCs 
(BM-MSCs) at the time of VF injury in a rabbit model. Three months post-injury there was 
a significant reduction in type I collagen deposition, reduced LP thickness and an 
improvement in viscoelastic properties compared to the saline treated control group(160, 
161). Vitamin A (topical retinoic gel) has also been used at the time of injury in a rabbit VF 
model, resulting in less collagen deposition in the treatment groups compared to the saline 
controls(162), as well as playing an important role in the repair and maintenance of the VF 
epithelium(163, 164).  
 
Corticosteroids, used primarily for their ability to dampen inflammation, have been suggested 
to also assist in wound healing, resulting in a significant reduction in collagen deposition 
post-injury, and inducing fibroblasts to begin synthesizing ECM with collagen, HA and 
fibronectin deposition most prominently at day 3-5 days post-injury in rabbit VFs (159, 165). 
The data from these studies show a positive therapeutic effect with corticosteroid delivery 
during the acute phase of wound healing. Further work is required to evaluate this beneficial 
effect on later stages of wound healing.  
 
Treatment of chronic VF scarring remains a challenge clinically. Several new approaches 
are currently under development, including cellular therapies (discussed further in sections 
1.11 and 1.13), local administration of growth factors and the use of scaffolds. In sulcus 
vocalis patients, autologous fascia transplantation has been reported with improvements in  
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phonation, mucosal wave function and glottal closure pattern(166-169). The data from these 
example studies demonstrates that implantation of fascia is beneficial in the treatment of this 
cohort of patients.  
 
Various animal models have investigated the use of pro-healing growth factors to enhance 
the wound healing process. bFGF is one such example, due to its known role in modulating 
stromal fibroblast proliferation and matrix production. Six months post-injection the authors 
report a reduction in tissue contraction, higher abundance of glycosaminoglycans (GAG), 
increased vibratory amplitude and a lower phonation threshold compared to saline treated 
control animals(72). The same group reported findings from their clinical study, suggesting 
significant improvement in glottal closure, acoustic and aerodynamic parameters from VF 
atrophy patients treated with bFGF(170). 
 
Scaffold materials have been used extensively by otolaryngologists for the treatment of 
patients with VF defects. Historically scaffold/biomaterials have been used to push the 
affected VF towards the midline, allowing for closer physical proximity during phonation. 
Synthetic materials such as silicone, polytetrafluoroethylene-teflon and 
polyhydroxyethylmethacrylate have been replaced with biodegradable materials, such as 
collagen matrix or fat, which also have the added advantage of being able to improve 
viscoelastic properties to that comparable with healthy VFs(171, 172). HA- and collagen- 
based hydrogels are the most common, both being major components in the native ECM of 
VF tissue. Bovine collagen has been used for the treatment of glottal insufficiency, but 
concerns over xeno-reactivity has led to a switch to autologous and micronized 
AlloDerm(173, 174). Commercially available composite materials including Gelfoam™ 
paste(175) Cymetra™(176), calcium hydroxylapatite(177), and HA derivatives such as 
Restylane™ and Hylaform™(178) have also been used in the clinic to enhance VF function.  
Hydrogel-based delivery of the anti-fibrotic growth factor, HGF, has also been reported in a 
canine model of VF injury, with data indicating that 3 months after treatment there was 
reduced PTP, decreased type I collagen, improved mucosal wave excursion and increased 
HA abundance compared to the saline treated control group(179). Similarly, pirfenidone 
delivery has also been considered, exhibiting both anti-inflammatory and anti-fibrotic effects 
in vivo and in vitro(180). New approaches for the treatment of chronic scarring are also being 
developed using PGE2. This bioactive lipid is a key anti-inflammatory mediator and 
additional exhibits anti-fibrotic effects through modulating the TGFβ1 signaling pathway, 
leading to de-differentiation of myofibroblasts into fibroblasts(181, 182). 
 
1.11 PRE-CLINICAL DEVELOPMENT OF MSC THERAPY FOR VF SCARRING 
 
A surgical and medical treatment to diminish VF scar formation has been met with limited 
success. Cell therapy is therefore being considered as a potential regenerative approach.  To 
date, cells such as autologous and allogeneic MSCs including adipose derived stromal cells 
(ADSCs)(183-185), fibroblasts(186, 187), ESCs(55), and induced pluripotent stem 
cells(188) have been used in pre-clinical animal models with the aim of resolving VF tissue 
damage and reducing scar formation with varying results.  
 
We have previously reported in a rabbit model of VF injury that local injection of human 
BM-MSCs at the time of injury, results in a reduction in levels of type I collagen, reduced 
LP thickness, and improved viscoelastic properties and histology compared to injured 
controls at 1-3 months(160, 161). Our team have further demonstrated that human BM-MSCs 
injected into the rabbit VFs nine weeks post-injury also successfully reduced LP thickness 
and restoration of viscoelastic shear properties comparable to uninjured animals(189). Our 
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findings have been validated in further models, including the rabbit, and with other sources 
of MSCs including ADSCs (reports summarized in table 1).  
 
Supporting studies have investigated in detail ultrastructural changes in fibrous components 
of the VF ECM post-MSC injection, demonstrating improved collagen structure (thinner 
fibrils and fibers) and organization, as visualized via atomic force microscopy(190).  Effects 
of MSC delivery have also been reported on scarring with relation to endogenous stromal 
fibroblasts. In a canine model, autologous BM-MSCs injected into injured VFs improved 
tissue regeneration(184), and laryngeal mucosa mesenchymal stem cells have been reported 
to transition myofibroblasts into fibroblasts(191). Likewise, autologous ADSCs injected into 
injured rabbit VFs, demonstrated a reduction in inflammation and fibrosis compared to 
controls(192). 
 
Hydrogels and scaffolds, as discussed in section 1.10, have also been combined with MSCs 
in developing novel therapeutics for VF scarring. Rabbit VFs have been transplanted with a 
composite gel composed of small intestine submucosa (a collagenous ECM material derived 
from the submucosal layer of porcine intestine) and rabbit MSCs, which aided in improving 
MSC survival for up to eight weeks in vivo, with a reported increase in HA accumulation 
within the ECM and a reduction in scarring(193). Atelocollagen sponge has also been 
combined with autologous canine BM-MSCs and injected into the sub-epithelial pockets of 
scarred VFs. The results demonstrated increased levels of HA, decreased collagen deposition 
and an improvement in mucosal vibration compared to the untreated group(194).  The use of 
HA-MSC hydrogels has been discussed further in section 1.12. 
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Table 1: Summary of pre-clinical in vivo studies conducted investigating the potential of stem and 
stromal cell populations in promoting vocal fold healing. Abbreviations: ADSC – adipose derived 
stromal cell; BM-MSC – bone marrow mesenchymal stromal cell; ECM – extracellular matrix; ESC 
– embryonic stem cell; HA – hyaluronan; HGF – hepatocyte growth factor; NA – not applicable 
 
Model Graft type Injected cells Associated materials 
Lapin Xeno BM-MSC(160, 161, 189, 
195)  
NA 
Lapin Xeno BM-MSC Porcine gel (193) 
Canine Auto BM-MSC/ADSC (196) NA 
Canine Auto BM-MSC Atelocollagen (184, 194) 
Rat Xeno BM-MSC(197) NA 
Rat Allo BM-MSC/ADSC(198) NA 
Rat Xeno BM-MSC ECM(183)     
Lapin Auto, 
Xeno 
ADSC(160, 185, 192, 195) NA 
Lapin Auto ADSC Collagen or HA(199) 
Lapin Xeno ADSC Alginate-HA 
hydrogel(200) 
Lapin Auto ADSC HA and HGF(201) 
Lapin Allo ADSC Fibrin hydrogel(202) 
Lapin Allo ADSC HA(203)  
Canine Auto ADSC Atelocollagen(204) 
Canine Auto ADSC(205) NA     
Canine Allo Laryngeal MSC(191) NA     
Lapin Xeno ESC(55, 206) NA 
 
1.12 HA DELIVERY OF MSCS 
 
As discussed in section 1.10.1, HA has been used safely in laryngology for the treatment of 
glottal insufficiency and for temporary augmentation in VF defects such as paralysis and 
atrophy. HA based hydrogels are biocompatible, and offer biomechanical advantages in VF 
treatments due to their viscoelastic and shock-absorbing capabilities(207). Their resorption 
rate can be modified based on the mode of chemical crosslinking used in gel formation, which 
allows adaptation for a variety of conditions as both a scaffold and cell/growth factor delivery 
vehicle(208, 209).  These properties make HA hydrogels an ideal option for delivering MSCs 
into the injured VF. When BM-MSCs are encapsulated within Extracel™, they maintain high 
viability leading to an increase in their survival (30 days post injection) and 
proliferation(210). In addition to enhancing cell survival, surrounding the cells with a HA 
rich environment encourages the production of an ECM profile more favorable for wound 
healing.  
 
The use of HA as a delivery vehicle for MSCs, of various sources, has been reported 
previously for VF injuries. ADSCs combined with HA gel before injection into injured rabbit 
VFs, demonstrated beneficial results, with the collagen contents decreasing and improving 
organization with remodeling after 12 months(199). Autologous fibroblasts encapsulated in 
a HA scaffold have also been suggested to improve rabbit VF structure and function(211). 
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Likewise, rat BM-MSCs encapsulated in ExtracelTM have also been reported to give a 
superior treatment outcome compared to BM-MSCs alone after one month in a rat model of 
VF injury(183). Injured rabbit VFs injected with BM-MSCs in HyStem® also reported 
minimal inflammation, improved viscoelasticity and changes in gene expression consistent 
with desirable ECM remodeling including lower levels of fibronectin, collagen (types I, II, 
and III), TGFβ1, αSMA, IL-1β, IL-17β and TNF-α compared to injury only animals, 
indicating that MSCs may expedite VF tissue repair after injury(212). Injectable HA has also 
been used in combination with other scaffold materials, including alginate. HA/mildly cross-
linked alginate hydrogel has been used in combination with ADSCs demonstrating 
improvements in VF architecture, with decreased collagen deposition and improvement in 
the viscoelastic properties(200). 
 
1.13  CLINICAL USAGE OF MSCS IN THE TREATMENT OF VF SCARRING  
 
Clinical MSC therapy has been proven to hold great potential for innovative intervention in 
the treatment of various diseases and disorders. In vitro, MSCs have demonstrated an 
important role in the inhibition of immune cell activation(213, 214), and within clinical 
studies this has been recapitulated, with MSC treatment reducing inflammation and exerting 
positive therapeutic effects on immune-mediated diseases such as steroid-refractory graft-
versus-host disease(215, 216) . The majority of these clinical studies have been conducted 
using intravenous delivery of MSCs (both autologous and allogeneic) with minimal side 
effects reported for BM-MSCs(217) .  
 
Trials using local injection of MSCs in clinical applications have increased over the last 
decade. Within the clinical setting for VF scarring, studies are still within their infancy. To 
date there is only 1 published case report conducted on a patient suffering with severe 
dysphonia at the time of treatment. The patient, who had already undergone 2 laryngeal 
phono-surgeries, had marked dysphonia. Autologous adipose derived stromal vascular 
fraction was injected into both scarred VFs. Final evaluation after 12 months demonstrated 
an improvement in vocal function, stable phonation with no breathiness. In addition, 
significant improvement in VF vibration was also observed.  No severe side effects were 
observed due to cell administration(218). This research group also completed a phase I trial 
in 2018, in 8 patients using the above approach, but the data remains to be reported 
(ClinicalTrials.gov ID: NCT02622464).  
 
Basic knowledge regarding the safety of local MSC administration has been gleamed from 
clinical studies in other indications; for example, intradiscal implantation of autologous BM-
MSCs has been used in patients suffering from degenerative disc disease. Significant 
improvements were observed in overall subjective symptoms such as reduced pain, increased 
function and reduced disc bulge size in the majority of the patients in the 6 years of follow-
up study(219). ADSCs in HA hydrogel have also reported to significantly improve disc 
function in patients with chronic discogenic lower back pain(220). Similar positive findings 
have also been reported regarding the use of local administration for tissue repair responses, 
including the closure of fistulas in Crohn’s disease patients with, as previously reported, no 
negative side effects of MSC treatment(221).  Intramuscular injection of allogenic MSCs 
have also been safely employed for the treatment of digital ulcers in systemic sclerosis 
autoimmune disease(222).  
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2 AIMS OF THE THESIS 
 
hESCs have the capacity of self-renewal and pluripotency, and MSCs due to their 
multipotency and anti-inflammatory properties, have been considered valuable resources in 
regenerative medicine. The overall aim of this thesis was to investigate the mechanisms by 
which human ESCs and BM-MSCs enhance wound healing in injured rabbit VFs, and 
translate this knowledge to a novel cell therapy for patients with severe voice disorders.   
 
Study I  
To evaluate the effects of transplanted hESCs in the injured rabbit VFs after 3 months, as 
well as, to examine whether malignances or teratomas develop from hESCs transplantation 
in the VFs.  
 
Study II 
To establish whether local injection of BM-MSCs in a rabbit model of VF injury can 
modulate the early inflammatory response and promote the wound healing process. 
 
Study III  
To establish whether HA hydrogels offer a safe and efficient means for the delivery of BM-
MSCs in a rabbit model of VF injury. 
 
Study IV  
The aim of this phase I clinical study was to evaluate the safety of local delivery of autologous 
BM-MSCs in patients with VF scarring. The secondary aim was to functionally examine the 
effects of BM-MSC delivery on the restoration of VF function.  
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3 METHODOLOGICAL APPROACHES 
 
Detailed description of materials and methods used in each study can found in the respective 
papers (I-IV) included in this thesis. This section provided an overview of materials and 
methods used in the presented studies.  
 
3.1 MATERIALS 
3.1.1 Ethical approvals  
 
Ethical approvals for the use of human ESCs and BM-MSCs were obtained from the regional 
ethical review board, Stockholm, Sweden (hESC specific S29-06, S115-08, MSC specific 
ethics DNR 446/00, 2016/1582-3, 2018/1187-32). In vivo experimentation on rabbits for 
these thesis studies were obtained from the Swedish Board of Agriculture (N117/12 and 
N609/12). The clinical use of autologous BM-MSCs in patients with severe voice hoarseness 
was approved by the regional ethical review board, Stockholm, Sweden (DNR 2010/1650 
and DNR 2014/51432), with manufacturing of the cells conducted in Vecura under good 
clinical practice according to permissions from the Swedish National Board of Health and 
Welfare (952/2009, 6.3.3-8874/2011, 6.1.3-9791/2013, 6.1.3-16411/201). All MSC donors 
were informed and provided written consent as per the Helsinki declaration. The clinical 
study was registered at ClinicalTrials.gov, ID: NCT01981330. 
 
 
3.1.2 hESC preparation and characterization  
 
hESC cell line HS181(46;xx) was obtained by the local hESC network at Karolinska 
Institutet, provided by the Hovatta group(223). Briefly, the blastocyst was obtained from the 
consented patient and cells from the ICM isolated by removing zona pellucida. The obtained 
cells from ICM were transferred to culture dishes containing feeder cells (commercially 
obtained human foreskin fibroblasts), which were mitotically inactivated by 35 Gray 
irradiation as described(224). The cells were cultured in KnockOutTM Dulbecco's modified 
Eagle's medium (DMEM) containing glutamine (2nmol/1L), fetal calf serum (FCS; 20% 
[v/v]), β‐mercaptoethanol (0.1mmol/1), non-essential amino acids (1% [v/v]) and 
recombinant leukemia inhibitory factor (1µl/ml). After 9-19 days of initial growth, cell 
aggregates were sliced using glass capillaries in mild dispase solution, and aggregates 
removed from the culture dishes. Three or four undifferentiated hESC colonies were 
aspirated directly from culture plates in 1ml of saline solution. Cells were, injected in 0.1ml 
(approximately 104 cells) into the LP and/or to the superficial part of thyroarytenoid muscle 
of each VF. Passage 33 cells were used for study I included in this thesis. The undifferentiated 
hESCs were characterized by immunohistochemistry and confirmed as positive for Oct-4, 
TRA-1-60, and SSEA-4. 
 
3.1.3 Isolation of human MSC, expansion and characterization  
 
Human MSC were obtained from iliac crest bone marrow aspirate of healthy donors as 
previously described(216, 225). Briefly, the aspirate was diluted in 2 volumes of phosphate 
buffered saline (PBS) and centrifuged, before the mononuclear cells were separated on a 
Percoll® gradient and resuspended in DMEM‐low glucose supplemented with 10% (v/v) 
FCS, 100 IU/ml penicillin, 0.1 mg/ml streptomycin and 0.25μg/ml Fungizone®  (studies II 
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and III) or platelet lysate (final concentration equivalent of 9 x 107 platelets/ml; study IV). 
Cells were plated at a concentration of 1.6 x 105 cells/cm2 and cultured until they reached 80-
90% confluency. The adhering MSCs were detached using 0.05% trypsin-EDTA (studies II 
and III) or TrypLE™ (study IV) and further expanded, with a cell seeding density of 3 x 103 
cells/cm2.  MSCs were used at passages (P) 3-6 for studies II and III, and P1 for study IV. 
Differences in culture protocols exist for study IV in order to bring production in line with 
good clinical practice. Platelet lysate and TrypLE™ replaced FCS and trypsin-EDTA as 
xeno-free alternatives.  
 
MSCs used in studies II and III had been previously analysed for their capacity to 
differentiate down the adipogenic and osteogenic lineages(226). Flow cytometry was 
performed to confirm an MSC surface marker profile, as per ISCT minimal criteria, defined 
as CD73+, CD90+, CD105+, HLA-I+ and CD14-, CD34-, CD45-, and HLA-II- for MSCs used 
in all studies(57).  
 
3.1.4 Rabbit model of vocal fold injury 
 
New Zealand white rabbits, with a body weight of 3-4 kg, were used for the pre-clinical in 
vivo experiments conducted as part of studies I (n=16), II (n=31) and III (n=18). We have 
previously developed this rabbit model of VF injury in house, and extensively validated its 
potential in studying VF injury and the effects of locally administered cell therapy in 
promoting tissue repair(55, 74, 160, 161, 189, 206, 227). Rabbits represent a good  system, 
possessing large enough VFs to be able to successfully insert a laryngoscope and perform 
clinically relevant experiments. Furthermore, as discussed in section 1.1, rabbits possess a 
similar tissue architecture and healing response to that seen in humans, providing a model to 
access the wound healing cascade after injury within the VF and the potential therapeutic 
effects of MSC administration.   
 
All animals were carefully monitored before and after the surgical procedure, and 
experimentation was conducted in line with Karolinska Institutet’s internal regulations, as 
well as the Swedish regulations on animal care ethics conforming to Directive 2010/63/EU. 
Animals were anesthetized, and the larynx was viewed and examined using a pediatric 
laryngoscope and rigid endoscope (Figure 8). The injury was made in the superficial 
thyroarytenoid muscle, mimicking an injury akin to that would be induced during surgical 
resection of a VF scar within the clinical context.    
 
Figure 8: Rabbit vocal folds were visualized using a rigid endoscope, and injuries induced in the 
superficial thyroarytenoid muscle (arrow). hESCs and MSCs were injected immediately after injury 
into the wound site. 
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Animals were sacrificed at 6 and 12 weeks after hESC injections (approximately 104 cells/ 
per VF) in study I. Animals included in study II were sacrificed early time points (days 2 and 
4) to evaluate early response by MSCs (0.1-0,15x106 cells/per VF) to inflammation within 
the injured VF, and at later time points (up to day 25) to evaluate tissue architecture. In study 
III, we further investigated whether injection of the cells in a HA hydrogel carrier 
(AuxigelTM) may enhance tissue repair and/or retention of the MSCs at the site of injury, and 
also to establish whether the HA hydrogel could be resorbed, as well as, the long-term effects 
on tissue repair. For the clinical trial in study IV, the MSCs (0.5-2x106 cells in a 0.9% [v/v] 
saline solution supplemented with 10% AB Rh+ plasma vehicle) were injected into the 
scarred/damaged region of the LP and thyroarytenoid muscle using a Medtronic Xomed 27G 
laryngeal injector. 
 
3.1.5 Patient Characteristics  
 
Sixteen patients (11 males and 5 females) were selected for our phase I clinical study (study 
IV) based on inclusion criteria of severe hoarseness, vocal fatigue and/or VF scarring.  
Patients were receiving no other treatment and were >18 years at the point of inclusion. 
Exclusion criteria included no active inflammatory condition of the larynx or laryngeal 
papilloma, no diagnosed or suspected local malignancy, and female patients should not be 
pregnant. The patients were aged between 30-74, with a mean age of 54. All patients were 
negative for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus 
(HCV), human T lymphotrophic virus (HTLV), syphilis and lues. Videostroboscopic 
examination or a highspeed camera was used to diagnose the patients.  All the patients had 
shown manifest symptoms of strained voice and severe dysphonia, and all had undergone 
voice therapy treatment for 5-10 sessions by a speech and language pathologist with no 
improvement observed.  
 
3.2 METHODS 
3.2.1 Histological staining techniques 
 
Several histological staining techniques were employed in studies I, II & III to allow 
visualization of changes in tissue structure and cellular composition, in response to injury 
and MSC administration, within the VF tissue. Processing of tissue for histology consists of 
five different stages including fixation, processing, embedding, sectioning and staining(228). 
The chemicals used for fixation of the tissue preserve the natural tissue structure, as well as, 
protecting the cell structure from degradation. Various fixative chemicals can be used, but 
formaldehyde, as used in studies I, II and III, is the most common(229, 230). Paraffin wax 
used for the embedding process, maintains the integrity of the tissue during sectioning and 
transfer to slides for staining. 
3.2.1.1 Hematoxylin & eosin (H&E) staining  
 
This staining technique provides a simple means to visualize tissue architecture and a wide 
range of ECM, nuclear and cytoplasmic features. Introduced by Wissowzky in 1876, H & E 
has been extensively used in both biological and histopathological research(231). The blue-
purple color of hematoxylin stains nucleic acids and eosin stains proteins pink, without 
specificity. In tissue, the nuclei stain blue and cytoplasm, ECM and erythrocytes appear in 
different shades of red-pink. H & E staining was used in studies I, II and III to verify basic 
tissue histology after injury of the VFs, the degree of inflammation by viewing lymphocytic 
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infiltrate and the level of fibrosis. Although the H&E stain is useful in understanding 
abundant tissue structural information along with morphological changes, limitations do 
exist. Its non-discriminate staining of ECM components and cells means further analysis is 
required for detailed investigation of individual cell types and changes in tissue composition.  
3.2.1.2 Masson’s trichrome staining  
 
Masson’s trichrome stain was employed in study II to localize connective tissue proteins, 
including total collagen fiber deposition and their structure and organization in the VF tissue 
after injury. This three color staining protocol, that has historically evolved from the original 
recipe reported by Mallory, was adapted by Masson and Gomori, before further modification, 
by Lillie, to that used in this thesis(232, 233). Analine blue is used to stain collagen blue, and 
muscle and cytoplasm color pink with staining using Beibrich scarlet-acid fuschin. Nuclei 
are stained with Weigert’s iron hematoxylin. The use of acetic acid allows color development 
to appear more delicate and transparent, whilst Bouin’s solution intensifies the final 
coloration for contrast between the stains.   
3.2.1.3 Elastin Staining 
 
Staining of elastin composition and organization within the VF was performed using a 
hematoxylin-iodine-ferric chloride solution, with a Van Gieson counterstain, allowing the 
visualization of collagen fibers (red), muscle and other matrix molecules (yellow; study II). 
Elastin fibrils are refractive, and thinner than collagen fibers, usually appearing as branching 
fibers or sheets in the tissue(234). Ferric chloride and iodine bind to the elastin fibers and act 
as oxidizers in the conversion of hematoxylin to hematein(235). Since the sections are 
overstained in this manner, there is a need for differentiation, which is achieved by use of a 
diluted ferric chloride solution, allowing the tissue-mordant-dye complex to be broken down. 
One disadvantage of this stain is that differentiation of each slide cannot be achieved using a 
standardized procedure, rather each section requires monitoring during the process, as the 
time required depends on the amount of elastin present in the tissue.  
3.2.1.4 Alcian blue staining  
 
Alcian blue solution contains copper pthalocyanine and is a polyvalent basic dye that carries 
a positive charge. It primarily stains acidic polysaccharides, such as GAGs, as well as, 
sulfated and carboxylated acid mucopolysaccharides and glycoproteins (sialomucins)(235). 
This method was used to visualize the HA delivery vehicle after injection into the injured 
VFs in study III.  
 
3.2.2 Parallel plate rheometry 
 
Parallel plate rheometry was used measure the viscoelastic properties of VF tissue. We 
employed this technique in study I to verify viscoelastic shear properties and evaluate the 
functional effects of hESC injection on VF vibrations. This method was performed as 
described previously(30, 227). In this experiment, an AR 2000 rheometer was used, 
consisting an 8mm diameter stationary lower plate separated by 0.5mm from a rotating upper 
plate. This produces sinusoidal shear forces with small amplitude oscillations at increasing 
frequency (0.01-15Hz). The VF tissue samples were placed into the rheometer and 
measurements performed in the linear region. The measurement of material resistance to 
shear flow (dynamic viscosity n’ Pa.s) and material stiffness (elastic modulus, G´ in Pa) was 
recorded and analyzed.     
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3.2.3 Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) 
 
This assay was developed to detect localization of apoptotic DNA fragments in tissue by 
Gavriell et al(236). This assay was utilized to detect levels of cell death close to the injury 
site within the VF and establish whether MSC administration could ameliorate this damage 
(study II). Briefly, the tissue is incubated with labeling buffer containing biotinylated 
deoxyuridine triphosphates, which are coupled to the 3’ hydroxyl terminus of DNA by 
terminal deoxynucleotidyl transferase(237). Binding of the labelled nucleotides to the DNA 
ends is visualized by incubation with streptavidin-conjugated horseradish peroxidase (HRP), 
and development using 3,3’-Diaminobenzidine (DAB). Methyl green counterstain is cationic 
and will bind to DNA, exhibiting greater uptake by cells, which are pyknotic, mitotic, or 
apoptotic(238). Cells with fragmented chromatin, a characteristic of apoptosis, appear dark 
brown after staining. However, this assay can be limited by the fact that swollen, necrotic 
cells can also exhibit brown staining within the cytoplasm, as well as, the nucleus. Likewise, 
eosinic cells can exhibit greater methyl green uptake, therefore the need for appropriate 
controls and careful interpretation of the data is essential.   
 
3.2.4 Immunohistochemistry  
 
Immunohistochemistry (IHC) and immunofluorescence (IF) are essential methods for a 
biological researcher to verify the distribution, of a given molecule within tissue sections via 
antigen-antibody reaction. In study II IHC was employed to detect CD163 expression on the 
surface of monocytes/macrophages within the injured VF. The sections were stained with a 
monoclonal, murine antibody raised against human CD163, that had been demonstrated to 
cross-react with the lapin antigen. A biotinylated goat anti-mouse IgG secondary antibody 
was used to provide the substrate for binding of avidin, and subsequently HRP. Color 
development was performed using the chromogenic dye DAB, which when oxidized by HRP 
forms a brown precipitate that can be observed using bright field microscopy(239). Mayer’s 
hematoxylin was used as a nuclear counterstain as previously described.  
 
In studies I and III we performed IF for detection of type I collagen within the VF tissue 
using a monoclonal, murine antibody against bovine type I collagen, that cross-reacts with 
the lapin antigen. A Cy™3 conjugated goat anti-mouse IgG secondary antibody was used in 
conjunction, allowing visualization of the collagen fibrils. A VECTASHIELD® mountant 
containing the nuclear counterstain, 4′,6-diamidino-2-phenylindole (DAPI) was added to the 
stained tissue to prevent bleaching of the fluorescent signal and stain nuclei blue. Relative 
type I collagen levels were evaluated using in house custom software.  
 
The IHC method is useful in understanding and analyzing positive signals in larger areas of 
tissue, while IF allows subcellular localization of target molecules. The number of target 
molecules that can be detected also varies between these methods. IHC can be used for two 
molecules including counterstaining, whereas IF can be used to visualize multiple target 
molecules, limited only by the number of fluorophores available(240, 241).  However, IHC 
and DAB based detection provides permanent signals, and stained sections can be stored 
forever. In contrast, fluorescence signals are bleached if they are exposed to a light source or 
in long-term storage.  
 
The IHC stained tissue sections from study II were scanned using a 3DHISTECH MIDI 
Scanner, digital microscope(242). This technology provided high resolution, whole slide 
imaging, with digital images importable into the associated Pannoramic Viewer software. 
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The generated images were then compatible with CellProfiler software, allowing quantitative 
assessment of CD163 levels within the tissue(243, 244).  
 
The major limitation of IHC and IF within these studies was the lack of antibodies suitable 
for use in rabbit tissue. During the early phases of study II, significant time and effort went 
into testing and validating appropriate antibodies for visualization of the T cell markers CD3, 
CD4 and CD8, the macrophage marker CD11b, and immunomodulatory molecules 
associated with MSC mode of action IL-6, IL-10 and IDO. These studies proved 
unsuccessful. This is the primary reason why only CD163 was subsequently used in the 
published manuscript.  
 
3.2.5 Fluorescence in situ hybridization  
 
Fluorescence in situ hybridization (FISH) is a molecular cytogenetic technique widely used 
in the field of cytology. This technique, developed in the early 1980s uses the binding of 
fluorescent DNA probes to complementary nucleic acid sequences allowing their 
visualization via fluorescence microscopy(245). This technique was employed in studies I, 
II and III to detect human MSCs at various time points after their local injection into injured 
rabbit VFs. This exploitation of species differences between ESC, MSCs and VF tissue, 
allowed us to use FISH as a measure of ESC and MSC persistence in the tissue after 
administration. This method had been previously established within our lab for this purpose 
in the rabbit VF injury model(55, 160, 161, 189, 206).  
 
Tissue samples are denatured at 95°C, before treatment with pepsin A, a protease which can 
digest cytoplasmic proteins. Both of these steps are essential to ensure optimal binding of the 
DNA probe. For the purposes of these studies we used CEP X (DXZ1) SpectrumGreen Probe 
to detect ESCs and SpectrumRed™ Y chromosome whole genomic probe to detect MSCs 
(from a male donor) within the tissue. The probe was denatured to ensure optimal binding to 
its complementary DNA sequence and hybridized overnight at 38°C. Slides were mounted 
with VECTASHIELD® containing DAPI counterstain as previously used in section 3.2.4 for 
IF.  
 
3.2.6 Quantitative real-time polymerase chain reaction  
 
Quantitative real-time polymerase chain reaction (qPCR) is a commonly used method in 
molecular biology to quantity gene expression, which was developed in 1992 for target 
amplification and detection using either fluorescent dyes or probes. This method allows the 
quantification of the exact amount (relative or absolute) of amplified gene expression(246).  
Total RNA was extracted from rabbit VF tissue (studies II and III) or human MSCs (study 
III). Tissue from the animal studies was preserved in RNAlater® solution prior to processing, 
ensuring stability of the RNA within the samples and inactivating RNase activity. Total RNA 
was extracted from tissue using the Ribopure™ RNA Isolation kit. This kit contains TRI 
Reagent® to homogenize the tissue, prior to treatment with bromochloropropane, a less toxic 
equivalent to chloroform, which aids in the separation of the nucleic acids. For isolation of 
total RNA from MSCs, cells were lysed in RLT buffer supplemented with ß-mercaptoethanol 
(to degrade RNases), using the RNeasy® mini kit.  Both the Ribopure™ and RNeasy® kits 
use a spin column-based method for separation of RNA, binds the nucleic acids to the filter 
membrane, allowing washing with ethanol and finally wash solution, to remove any 
contaminating ethanol, which would inhibit downstream enzyme activation. RNA is eluted 
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in molecular grade water, before quantification and assessment of quality using a NanoDrop 
spectrophotometer.  
 
cDNA template generation from eluted RNA was performed using the RT2 first strand kit 
(VF tissue) or high capacity cDNA reverse transcriptase kit (MSCs). In study II, gene 
expression studies were conducted using standard qPCR methodology, whereas in study III 
this method was used in combination with an RT2 profiler system consisting of a panel of 84 
rabbit inflammatory cytokines and receptors. This array was used to generate preliminary 
data as to the key inflammatory cytokines upregulated in response to VF injury within the 
rabbit. Analysis of data from 2 injured rabbit VFs and 1 uninjured, control VF, provided us 
with a battery of cytokines, which provided information as to the key cytokines the injected 
MSCs may be exposed to and therefore modulate. These included IL-1b, IL-8 and CCL4 
which were further investigated at mRNA and protein levels in studies II and III.  
 
Standard qPCR was performed using human MSC cDNA gene specific primers generated 
using Roche’s universal probe library. In contrast such extensive databases for the rabbit 
genome are not available and therefore gene targets investigated using qPCR in the rabbit 
tissue was limited by those commercially available. For both human and rabbit target genes, 
the house-keeping gene b-actin was used for normalization of expression levels.  
 
3.2.7 Preparation of hyaluronan hydrogel 
 
AuxiGel™, used in these studies, combined an aldehyde derivative of HA with poly-vinyl 
alcohol (PVA) to generate a chemically modified HA hydrogel in studies III and IV of this 
thesis. Both HA and PVA components are mixed with PBS at concentrations of 15mg/ml and 
2.5mg/ml respectively. HA and PVA are loaded into 2 1ml sterile luer-lock syringes at a ratio 
of 3:1, previously optimized to ensure that stiffness of the gel generated would be suitable 
for combination with the MSC suspension, and injectable through a 27G needle upon 
delivery. Both syringes were connected using a luer-lock adapter and the components mixed 
at room temperature for 5-10 cycles, 1 cycle determined as movement of all the material from 
1 syringe to the other with duration time of 5 to 20s (for optimal mixing, while minimizing 
air bubble formation) for each cycle.  
 
For experiments in study III, the HA hydrogel was mixed with MSC cell suspension in cell 
culture media (in vitro experiments) or PBS (in vivo studies) before injecting through a 27G 
needle. In study IV, where MSC: HA hydrogel mix was injected into the patient’s VF tissue, 
MSCs were suspended in 0.9% (v/v) saline supplemented with 10% (v/v) human AB Rh+ 
plasma.   
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Figure 9: Schematic illustration of Auxigel™ preparation. Hyaluronan (HA) and poly-vinyl alcohol 
(PVA) components are mixed in connecting syringes, generating a chemically cross-linked hydrogel. 
The figure is reproduced with permission from Piskounova et al., Macromolecular Material and 
Engineering, 2011, 296,944-951.  
 
3.2.8 Determining the effect of HA on MSC number  
 
We used the CyQUANT® Cell Proliferation assay to assess the effect of HA gel 
incorporation on MSC viability and proliferation in vitro. The key component of this assay 
is the CyQUANT® GR dye that displays a large fluorescence enhancement when it binds 
nucleic acids. MSCs that were incorporated in the HA gel were snap-frozen at days 0, 1 and 
3, and subsequently lysed in buffer containing the CyQUANT® GR dye, providing access to 
the nucleic acids(247). This system is sensitive, exhibiting a linear detection range, using 
fluorimetry, between 50-50,000 cells and is not dependent on cellular metabolic activity like 
assays such as 3H-thymidine uptake. The primary advantage of this sensitivity is that relative 
increases and decreases in cell number can be evaluated compared to the day 0 reading. This 
allowed us to use this assay for both the purpose of investigating cell proliferation and 
survival within the HA gel in study III. 
 
3.2.9 Establishing the effect of HA on MSC migration and invasion in response to pro-
inflammatory signals 
 
To verify whether HA hydrogel incorporation modulated cell migration, chemotaxis and 
invasion in response to pro-inflammatory factors, the Cultrex 96 well Collagen I Cell 
Invasion assay was employed in study III. This high-throughput, 96 well format, assay uses 
a Boyden chamber approach to evaluating cell migration through an 8μm polyethylene 
terephthalate membrane. In order to evaluate migration, MSCs +/- HA hydrogel 
incorporation were applied to the top chamber and allowed to migrate through the uncoated 
membrane. The addition of our selected pro-inflammatory factors upregulated during early 
VF injury response, IL-1β, IL-8 and CCL4, were added to the bottom chamber to evaluate 
directed migration of the MSCs. To also evaluate invasion potential of the MSCs, the 
chamber membrane was precoated with type I collagen, providing a matrix, as would be seen 
in the VF tissue, which the MSCs would need to digest and remodel in order to migrate 
through to the underside of the chamber. After 24 hours incubation at 37oC, the migrated 
cells were dissociated from the membrane and stained with calcein-AM. This dye freely 
passes through the cell membrane and is cleaved by intracellular esterases to calcein, which 
fluoresces brightly and allows cell number to be quantified by fluorimetry.  
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3.2.10 Enzyme linked immunosorbent assay 
 
In study III, sandwich enzyme linked immunosorbent assays (ELISA) were used to evaluate 
secreted levels of IL-6, IL-8, HGF, VEGF and TGFβ1 by MSCs +/- HA hydrogel 
incorporation in response to IL-1β, IL-8 and CCL4 exposure. Monoclonal antibodies targeted 
against the human soluble factor of interest were coated on to high-binding ELISA 96 well 
plates overnight at room temperature. Residual binding sites were blocked using a bovine 
serum albumin buffer. Conditioned media from MSCs exposed to the above conditions, or a 
standard curve of the purified protein of interest (concentration range for linear detection 
optimized by the manufacturer) is then incubated in the plate for 2 hrs to establish binding of 
the ligand to the antibody. The plates are, after washing, incubated with a biotin tagged 
secondary antibody raised against the human protein of interest. Binding of the secondary 
antibody can be detected through incubation with HRP conjugated streptavidin, before 
development of the colour using a 1:1 mix of hydrogen peroxide and tetramethylbenzidine. 
This reaction is stopped with the addition of sodium hydroxide, which generates a stable 
yellow product. The intensity of this product linearly correlates with the concentration of the 
protein of interest in your test sample.  
 
Evaluation of TGFβ1 using these assays requires prior preparation of your sample prior to 
incubation with the primary antibody. TGFβ1 can exist in both latent (not immunoreactive) 
and bioactive forms and therefore in order to measure total TGFβ1 levels, samples are 
pretreated with hydrochloric acid to remove the latent peptide, rendering a detectable form 
of the growth factor. Serum containing media, in which the MSCs are grown, contains a 
considerable amount of latent TGFβ1, as well as, other growth factors. It is therefore 
important than unconditioned media controls, at each dilution that the samples will be tested, 
is also added to the plate in order to give an accurate background control. As there is batch 
to batch variability in the contents of serum, this background control is matched to each 
experiment run. 
 
3.2.11 Clinical evaluation of vocal fold function 
 
The patients included in the clinical study (study IV) were selected with manifestation of 
symptoms of severe voice problems or dysphonia. Both methods of clinical assessment and 
self-reporting were utilized in this study. Initially we performed high-speed examination and 
videostroboscopy to examine the VF vibration and function. These methods allow the 
identification of various parameters of VF function such as VF edges, closure, vibratory 
characteristics (vibration symmetry without irregularity or stiffness), and structural 
characteristics (edema or masses that interfere with phonation)(248). The high-speed 
videostroboscopy method allowed visualization of glottal dysphonia, and also recording of 
VF motions with enhanced temporal resolution(249). In our studies, we used a HiSpec 1 
camera for high-speed recordings of VF vibration, which were digitalized for further analysis 
using High-Speed Studio (HSS) software. VF glottal closure and amplitude during vibration 
was digitized, normalised to membranous VF length and measured with the HSS software. 
The open/closed coefficient during vibrations was calculated using HSS from kymograms. 
VF parameters such as glottal closure, amplitude of vibration and mucosal waves were 
analyzed by three selected phoniatricians, who were blinded regarding the patients’ clinical 
history. Video recordings were rated in a pairwise manner from pre-operative recordings and 
at 12 months after surgery.  
PTP was recorded as a measurement of VF elasticity and vocal onset effort(4). This was 
measured from the minimal intra-oral pressure using a pressure transducer and a 4mm plastic 
catheter placed in the corner of the patient’s mouth during repeated “pa” syllables at habitual 
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pitch.  The Voice Handicap Index (VHI) scale was used to rate a patient’s subjective voice 
symptoms consisting of physical, functional, emotional aspects of daily living. This 
standardized scale consists of 30 questions or statements validated for the Swedish language, 
for the patients to answer(250). 
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4 RESULTS AND DISCUSSION 
 
4.1 STUDY I 
 
Tissue injury or scarring in the VF disrupts viscoelastic properties in the tissue and leads to 
stiffness in the LP, causing severe voice problems(3, 4). hESCs have been considered as a 
potential resource for cell therapy in regenerative medicine. In our previous study, hESCs 
injected into injured rabbit VFs demonstrated human tissue generation (cartilage, epithelium, 
glands and muscle) close to the injection site in the VF tissue(55), improving viscoelasticity 
of tissue and VF function.   
4.1.1 The role of ESCs in tissue formation and wound healing 
 
ESCs have been shown to aid tissue repair within several animal models(251). For example, 
ESCs have been demonstrated to promote cutaneous repair in nude mice through 
differentiation into basal keratinocytes(252, 253). Likewise, in disease models, ESCs have 
been suggested to improve symptoms of Parkinson’s disease via neuronal 
differentiation(254-256). Furthermore, their differentiation into hepatocytes and 
chondrocytes(257-260), pancreatic tissue(261, 262) and blood cells(263, 264) have also been 
reported. Due to their capacity to self-renew and pluripotency, ESCs may have been 
considered as a potential resource in regenerative medicine(265). Based on knowledge from 
the literature, and the results obtained from our previous study on the histology and properties 
of  VFs one month after ESC injection(55), we now designed a study to see the long term (3 
months) effects of hESCs in the injured VF tissue. The findings from this study are described 
below. 
 
4.1.2 Key findings  
 
1) hESC administration into injured rabbit VFs  increased viscoelastic properties to those 
comparable to normal VFs.  
2) Histology was improved and indicated normal VF architecture after hESC treatment. 
3) IHC results depicted reduced collagen deposition in the injured VFs treated with hESC 
compared to untreated VFs. 
4) LP thickness was reduced significantly in hESC treated VFs compared to untreated 
VFs. The difference in the thickness of the LP between hESC treated VFs and normal 
VFs was not significant. 
5) hESC derivatives such as teratoma and malignances were not found in the treated VFs 
at 3 months.  
6) Transplanted hESCs were detected after six weeks in the injured VFs. 
 
4.1.3 Discussion  
 
Our first study indicated that local injection of hESCs improved VF vibration after one 
month(55). The findings of this 3 month study confirm the positive effects of hESC injection 
and indicate that the effect is sustained over time. The results from H&E staining indicated 
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that the VF tissue organization was improved with hESC treatment, consistant with reduced 
LP thickness. Additionally, type I collagen levels were significantly reduced in the hESC 
treated VFs compared to untreated, injury only controls. The injected hESCs stayed close to 
the injection site within the LP and muscle up to six weeks after transplantation. No teratomas 
and malignances were evident post-hESC injection after three months in the treated VFs.     
 
Although our findings indicate beneficial effects of injecting hESCs into the injured VFs in 
both our 1 and 3 month studies, there are several other obstacles that remain to be resolved, 
regarding these cells, before moving onto further basic research or into clinical application. 
One limitation for our research is that hESCs are not known be immune suppressive in the 
presence of inflammation. As our studies deal mainly with inflamed or scarred VF tissue, we 
decided to switch to using BM-MSCs as a potentially better cell source to conduct further 
studies in our research discipline. 
 
4.2 STUDY II 
 
Damage and scar formation within the VFs leads to significant changes in tissue 
viscoelasticity and shear strength, disturbing the normal mucosal wave during speech or 
phonation resulting in severe voice problems(5). Previous studies, including those from our 
group, have demonstrated that local administration of MSCs can reduce scar formation in the 
injured and scarred VF(160, 161, 183, 189, 212).  Limited information regarding the MSC 
mode of action in promoting these healing effects has been delineated, therefore in this study 
we investigated the effect of MSC injection on the early inflammatory phase of wound 
healing after VF injury. 
4.2.1 MSC modulation of acute injury response 
 
MSCs have been shown in multiple organ systems to play a pivotal role in tissue homeostasis 
and repair(219-222, 266-269).Their ability to home to sites of injury and modulate the 
activity of both immune cells and resident stromal fibroblasts has established fundamental 
reparative roles for MSCs in all phases of the healing cascade(142, 270, 271).  
 
No effective treatment for chronic scarring within the VF exists currently, but great promise 
has been placed on the development of novel cellular therapeutics, including the use of 
MSCs. The aim of this study was to ascertain how local administration of MSCs during the 
acute inflammatory phase, as would be induced upon surgical resection of VF scar tissue, 
could modulate the healing response.  
  
4.2.2 Key findings  
1) MSC administration expedited the resolution of tissue inflammation as demonstrated 
by decreased lymphocyte infiltrate within the VF tissue of treated animals compared to 
injury only controls.  
2) These histological observations were further supported by a decreased mRNA 
expression, in the VF tissue, of the pro-inflammatory cyto/chemokines IL-1β and IL-8 
at day 2 compared to injury only control animals.  
3) Decreased mRNA expression of the monocyte recruitment and activation factors M-
CSF, monocyte chemoattractant protein -1 (MCP-1) and CCL1 within the MSC treated 
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VF tissue compared to controls, further indicated that the wound healing response was 
accelerated by the presence of MSCs, promoting inflammation resolution and transition 
to the proliferative phase of the wound healing response.  
4) Increased levels of the anti-inflammatory macrophage marker, CD163, was observed 
in the MSC treated VFs compared to controls, supporting an immunomodulatory role 
by the MSCs. 
5) MSCs appeared to reduce the level of cell death at the site of injury compared to injury 
only controls.  
6) Inflammation resolution coupled to improved repair tissue composition, with the 
collagen architecture organized parallel to the tissue surface, akin to that seen in healthy 
VF tissue. 
7) Despite multiple therapeutic effects on tissue repair in the VF, low level persistance of 
the administered MSCs was seen. 
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Figure 10: Summary flow diagram illustrating the study design employed in study II. Abbreviations: 
FISH – fluorescence in situ hybridization; H&E – hematoxylin and eosin; IHC – 
immunohistochemistry; MSCs – mesenchymal stromal cells; TUNEL - Terminal deoxynucleotidyl 
transferase dUTP nick end labeling. All composite images are used with permission. MSCs: Wu W et 
al., Molecular and Cellular Proteomics. 2018 Aug;17(8):1502-1514(272) 
 
4.2.3 Discussion  
 
This study used our previously optimized rabbit model to induce an acute injury and evaluate 
the effect of local administration of MSCs at the time of injury in enhancing the healing 
process.  
 
Histology, in conjunction with qPCR analyses, confirmed a large lymphocytic infiltration 
post-injury, which was quickly resolved with the administration of MSCs. Furthermore, 
significant lowering of levels of pro-inflammatory cytokines, including IL-1β and IL-8 was 
seen at the mRNA level. This enhanced resolution of the inflammatory phase of the wound 
healing process could be attributed to both a decreased level of cell death in response to injury 
and promotion of an anti-inflammatory milieu that encompasses a skewing of M1 pro-
inflammatory macrophages and infiltrating monocytes to an anti-inflammatory CD163+ M2 
phenotype. This change in inflammatory milieu also impacted on the production and 
organization of the ECM.  Collagen organization was markedly improved in the MSC treated 
VFs, appearing densely packed and parallel to the tissue surface. These observations 
correlated well to the improved functionality associated with MSC treated VFs that we and 
others have previously reported(160, 161, 183).  
 
In line with our previous observations, only low-level persistence of MSCs was evident 2 
days post-injection. These findings support the notion that MSCs do not engraft into the VF 
tissue but are able to promote healing via indirect mechanisms through the local immune and 
stromal environment.   
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4.3 STUDY III 
 
Local administration of MSCs into VF tissue has demonstrated enhancement of tissue 
regeneration and restoration of VF functions(160, 161, 189). Limitations exist however, in 
the delivery of MSCs within a liquid suspension. These include risk of cell suspension 
leakage, and an inability to effectively treat large and critical size defects. The aim of this 
study was to evaluate whether MSCs delivered in HA hydrogel would offer a safe and 
effective alternative to liquid delivery, holding the cells at the site of injury site and further 
supporting tissue repair, with the hydrogel acting as a scaffold for larger defects.  
 
4.3.1 HA for the local delivery of MSCs 
 
HA is a natural component of the VF ECM, contributing to its biomechanical properties, as 
well as acting as a key regulator of cellular interactions and tissue repair processes(26, 27). 
In its hydrogel form, HA has been successfully used as a delivery vehicle for cells and 
bioactive factors, as well as a tissue repair agent in its own right(273, 274). This GAG is a 
non-immunogenic, biocompatible material that is actively resorbed by the tissue, making it 
an ideal agent for clinical usage, where for over a decade, it has been used in the treatment 
of glottal insufficiency(275). 
 
4.3.2 Key findings 
1) HA hydrogel incorporation of MSCs does not negatively impact their viability or 
function, but does delay migration compared to liquid suspension cells. 
2) MSCs modulate their mRNA expression of matrix remodeling genes from HAS, 
HYAL and MMP families in response to HA gel incorporation and exposure to pro-
inflammatory cyto/chemokines.  
3) MSCs contained within HA hydrogels remain responsive to their extracellular 
environment, upregulating the secretion of immunomodulatory factors, such as IL-6, in 
response to pro-inflammatory cyto/chemokines. 
4) MSCs delivered in HA hydrogel, in a rabbit model of VF injury, demonstrated less cell 
suspension leakage compared to liquid suspension controls.  
5) Hydrogel delivery of MSCs did not induce edema and was resorbed within the 1 month 
follow-up time in rabbits. 
6) MSCs reduced inflammation and promoted repair of the VFs, with no significant 
differences noted between liquid and HA delivery vehicles. 
7) Delivery of the MSCs in HA hydrogel did not improve persistance of the cells within 
the VF tissue. 
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Figure 11: Summary flow diagram illustrating the study design employed in study III. Abbreviations: 
FISH – fluorescence in situ hybridization; HA – hyaluronan; H & E – hematoxylin and eosin; IHC – 
immunohistochemistry; MSCs – mesenchymal stromal cells; qPCR – quantitative polymerase chain 
reaction. All composite images are used with permission.  MSCs: Wu W et al., Molecular and 
Cellular Proteomics. 2018 Aug;17(8):1502-1514(272)  
 
 
4.3.3 Discussion 
 
The principle aim of this study was to evaluate whether delivery of MSCs within a HA 
hydrogel offered a safe alternative to current liquid delivery vehicles, and address limitations 
in current delivery methods through holding the MSCs at the site of injury, potentially 
increasing their longevity, minimizing leakage and providing a scaffold akin to the ECM.  
 
Our animal study demonstrated that HA hydrogel delivery of MSCs into VF defects was safe, 
with no serious adverse side effects, such as edema or inflammation within the VF, in 
response to the gel. We furthermore conducted a number of in vitro analyses to confirm that 
the MSCs remained viable within the gel and exhibited a delayed, although not halted, 
migration compared to MSCs in liquid suspension. The presence of a collagen matrix, as seen 
in the invasion assay setup, did enhance migration out of the HA gel, potentially explaining 
why there was no increased persistence of the MSCs within the VF tissue with HA delivery.  
MSCs remained responsive to extracellular pro-inflammatory cytokines relevant to the acute 
injury milieu that would be seen in the rabbit VF, upregulating the secretion of 
immunomodulatory factors, such as IL-6 and modulating their expression of key matrix 
remodeling genes.  This was corroborated by the in vivo analyses demonstrating consistently 
reduced inflammation in the presence of the MSCs, irrespective of the delivery vehicle.  
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We concluded that HA hydrogels can be safely employed for the delivery of MSCs into 
injured VFs, minimizing leakage of cell suspension during injection and providing a scaffold 
supporting the healing of critical sized defects.  
 
4.4 STUDY IV 
 
Despite numerous pre-clinical approaches to treating VF scarring, no effective clinical option 
exists to date. Local implantation of fillers such as fat and HA demonstrate some therapeutic 
effect, softening the scarred tissue, as well as, injection of growth factors such as HGF and 
bFGF(208, 276-278). These effects are short lived however, not addressing the underlying 
pathophysiology of the condition. The aim of this study was to take the knowledge we had 
learnt from our pre-clinical work, and conduct a phase I/II clinical trial to evaluate the safety 
of administering autologous human BM-MSCs to patients suffering with severe voice 
problems.  
 
 
Figure 12: High-speed video kymogram of vocalfold (VF) vibration and glottal closure at the 
midline, demonstrating that scarring inhibits both VF function and glottal closure. Top picture (A) 
shows vibrations from normal VFs and lower picture (B) shows reduced vibrations of a scarred right 
VF (star) with incomplete glottal closure. 
 
4.4.1 MSCs as a clinical treatment for VF scarring 
 
In addition to the trial reported in this thesis, only 1 clinical trial is registered on 
clinicaltrials.gov (ID: NCT02622464) for the use of stromal cells (autologous adipose-
derived stromal vascular fraction) in the treatment of VF scarring. This phase I study, 
completed in 2018, has yet to report its findings. A case report originating from the same 
research group has however reported positive findings in terms of safety and improvement 
in voice function for the female patient(218).  
 
Differences in MSC products, both in terms of cell source and manufacturing protocol, means 
there is an absolute need to determine safety and efficacy of individual cell products. In this 
study we used established protocols for the production of a clinical-grade autologous BM-
MSC product. With a primary endpoint of safety, we established that our BM-MSC product 
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was tolerated by patients who received a single dose of locally administered cells into VFs 
that had been resected of scar tissue in the same surgical procedure. Efficacy served as a 
secondary endpoint, with both clinical functional assays performed post-procedure, as well 
as, self-reporting of vocal function. 
 
4.4.2 Key findings 
 
1) In total 16 patients (11 males and 5 females, aged between 30-74) were included in the 
study with manifestation of severe dysphonia and strained voice.   
2) No adverse events were reported in response to MSC administration.  
3) Functional evaluation using high-speed laryngoscopy and PTP demonstrated 
improvements in VF function in 62-75% of the patients (dependent on parameter tested). 
4) VHI self-reports indicated improvements in vocal function in 8 of the patients, with the 
remaining patients reporting no significant change.  
 
 
 
Figure 13: Summary flow diagram illustrating the study design employed in study IV. Patients 
recruited to the phase I/II trial with damage and scarring to one or both of the vocal folds (VF). 
Autologous mesenchymal stromal cells (MSCs) were isolated from bone marrow harvested from the 
iliac crest, and expanded in monolayer to passage 1. MSCs were administered back to the patient at 
the time of surgical scar resection via local injection into the injured tissue. All composite images are 
used with permission. Human vocal folds: Zhang LT, Journal of Biomedical Science and 
Engineering, 2014 Feb;7(3):130-145(279). MSC expansion: Jakubikova J et al., Oncotarget, 2016 
Nov 22;7(47):77326-77341(280). Bone marrow aspiration: www.teresewinslow.com. Syringe and 
diagram of VFs:  smart server medical art (https://smart.servier.com).   
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4.4.3 Discussion 
 
This is the first phase I/II clinical study documenting use of autologous BM-MSC treatment 
in humans with VF scarring. Bringing together the knowledge gleamed in studies I and II, 
here we report clinical translation of our findings for the local administration of autologous 
BM-MSCs after surgical resection of VF scar tissue.  
 
No acute or long-term side effects were reported from MSC treatment in the 1 year follow-
up period post-injection. The most significant finding was in VF vibration capacity/elasticity, 
where VF vibration parameters were improved for 62-75% of the patients. Self-reporting, 
using the VHI, suggested that the majority of patients experienced improvement in phonation, 
being able to speak with less effort.  
 
For most of the patients, clinical improvements became evident after 3 months, indicating a 
long-term effect from the MSC treatment on healing, supporting our pre-clinical in vivo data. 
Less significant improvements were evident with larger defects, suggesting the potential need 
for further scaffold development to be used in conjunction with MSC administration. Further 
investigation of efficacy in a larger trial is warranted for validation of our reported findings.  
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5 SUMMARY OF MSC STUDIES 
 
  
 
Figure 14: Schematic summary of studies II, III and IV within this thesis. We demonstrate that local 
administration of mesenchymal stromal cells (MSCs) expedites and improves the quality of healing 
response within the injured vocal fold (VF), via the dampening of inflammation and cell death, while 
skewing the extracellular environment to an anti-inflammatory milieu. MSCs are able to do this 
whether delivered in liquid suspension or a hyaluronan (HA) hydrogel, with the latter option 
decreasing cell leakage and offering a practical delivery vehicle alternative to the former. Our findings 
were translated to a phase I/II clinical trial using autologous MSC injection into surgically resected 
VF scar tissue, demonstrating that this approach offers a safe and novel alternative for the treatment 
of patients with severe voice problems due to VF damage.  Abbreviations: IL – interleukin; PTP - 
phonation pressure threshold; VHI – voice handicap index. All composite images are used with 
permission from: human schematic diagram form smart server medical art (https://smart.servier.com). 
MSCs: Wu W et al., Molecular and Cellular Proteomics. 2018 Aug;17(8):1502-1514(272). MSC 
expansion: Jakubikova J et al., Oncotarget, 2016 Nov 22;7(47):77326-77341(280). 
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6 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
 
The development and use of cellular therapeutics, including MSCs, has grown exponentially 
over the last decade. The low immunogenicity of these cells, thanks to their potent 
immunomodulatory properties, has made them a popular choice for novel therapy 
development. MSCs can be isolated from a wide range of tissues, each with their own unique 
properties pertaining to their in vivo role. Much of the knowledge that we can gleam from the 
wider literature pertains to BM-MSCs, with this particular cell source most well characterized 
for their role in tissue repair responses and immunomodulation.  
 
VF scarring, due to trauma or other indications, represents significant morbidity for the 
patient, as well as, a huge societal burden related to healthcare costs and unemployment. For 
these patients there is no current effective treatment for this condition. Cell therapy, using 
MSCs, offers a novel approach to this, taking advantage of their ability to reduce 
inflammation when used in conjunction with surgical resection of scar tissue, and skewing 
of the endogenous VF cells to promote a functional tissue repair response.  
 
The studies conducted in this thesis have investigated ESC and MSC mode of action from 
basic in vitro investigations, through to an animal model of VF injury, and finally translation 
into the clinic in the form of a phase I/II trial. Collectively these studies demonstrate the 
potential for BM-MSC therapy in patients with severe VF damage to improve tissue 
functionality, and more importantly for the patient, improve phonation. Looking forward, 
these initial studies need to be clinically validated in a larger cohort. Safety, our primary 
endpoint, in this clinical trial was met, but there is a need to understand the efficacy of this 
therapy and how the clinical protocol can be advanced in terms of both an increase in the 
numbers of patients responding to treatment, and to address whether this approach would be 
suitable for other related conditions. Furthermore, we have highlighted the limitation of MSC 
administration for large, critical size defects in the VF. Studies remain to be conducted to 
understand how this issue can be addressed, including the value of scaffold-MSC or MSC-
growth factor/drug combinations. As technology and cell therapies develop, it is hoped that 
MSCs for the treatment of VF scarring will become an accepted standard line of care. 
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